B
Bruno Allolio
Researcher at University of Würzburg
Publications - 332
Citations - 24920
Bruno Allolio is an academic researcher from University of Würzburg. The author has contributed to research in topics: Adrenocortical carcinoma & Mitotane. The author has an hindex of 86, co-authored 332 publications receiving 22639 citations. Previous affiliations of Bruno Allolio include University of Cologne.
Papers
More filters
Journal ArticleDOI
Clinical practice guideline on diagnosis and treatment of hyponatraemia
Goce Spasovski,Raymond Vanholder,Bruno Allolio,Djillali Annane,Steve S. Ball,Daniel G. Bichet,Guy Decaux,Wiebke W. Fenske,Ewout J. Hoorn,Carole Ichai,Michael Joannidis,Alain Soupart,Robert Zietse,Maria M. Haller,Sabine S. Van Der Veer,Wim Van Biesen,E Nagler +16 more
TL;DR: The Clinical Practice Guideline on the diagnostic approach and treatment of hyponatraemia is developed as a joint venture of three societies representing specialists with a natural interest in hyponatonemia to obtain a common and holistic view.
Journal ArticleDOI
Clinical review: Adrenocortical carcinoma: clinical update.
Bruno Allolio,Martin Fassnacht +1 more
TL;DR: Future advances in the management of ACC will mainly depend on a better understanding of the molecular pathogenesis facilitating the use of modern cancer treatments (e.g. tyrosine kinase inhibitors).
Journal ArticleDOI
Adjuvant mitotane treatment for adrenocortical carcinoma.
Massimo Terzolo,Alberto Angeli,Martin Fassnacht,Fulvia Daffara,Libuse Tauchmanovà,Pier Antonio Conton,R. Rossetto,Lisa Buci,Paola Sperone,Erika Grossrubatscher,Giuseppe Reimondo,Enrico Bollito,Mauro Papotti,Wolfgang Saeger,Stefanie Hahner,Ann Cathrin Koschker,Emanuela Arvat,Bruno Ambrosi,Paola Loli,Gaetano Lombardi,Massimo Mannelli,Paolo Bruzzi,Franco Mantero,Bruno Allolio,Luigi Dogliotti,Alfredo Berruti +25 more
TL;DR: Adjuvant mitotane treatment had a significant advantage for recurrence-free survival in patients with radically resected adrenocortical carcinoma, and temporary dose reduction was needed in 13% of patients.
Journal ArticleDOI
Dehydroepiandrosterone replacement in women with adrenal insufficiency.
Wiebke Arlt,Frank Callies,J C van Vlijmen,Ines Koehler,Martin Reincke,Martin Bidlingmaier,Doris Dr Huebler,Michael Oettel,Michael Ernst,Heinrich M. Schulte,Bruno Allolio +10 more
TL;DR: Dehydroepiandrosterone improves well-being and sexuality in women with adrenal insufficiency and significantly improved overall well- being as well as scores for depression and anxiety.
Journal ArticleDOI
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Martin Fassnacht,Massimo Terzolo,Bruno Allolio,Eric Baudin,Harm R. Haak,Alfredo Berruti,Staffan Welin,Carmen Schade-Brittinger,André Lacroix,Barbara Jarzab,Halfdan Sorbye,David J. Torpy,Vinzenz Stepan,David E. Schteingart,Wiebke Arlt,Matthias Kroiss,Sophie Leboulleux,Paola Sperone,Anders Sundin,I G C Hermsen,Stefanie Hahner,Holger S. Willenberg,Antoine Tabarin,Marcus Quinkler,Christelle De La Fouchardiere,Martin Schlumberger,Franco Mantero,Dirk Weismann,Felix Beuschlein,Hans Gelderblom,Hanneke Wilmink,Monica Sender,Maureen Edgerly,Werner Kenn,Tito Fojo,Hans-Helge Müller,Britt Skogseid +36 more
TL;DR: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus Mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival.